Summit Securities Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Summit Securities Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$41.2K	Buy	+167	New	+$42.5K	﹤0.01%	594
2026 Q1	–	Sell	-202	Closed	-$80.3K	–	1032
2025 Q4	$80.3K	Buy	+202	New	+$89.4K	0.01%	517
2024 Q4	–	Sell	-1	Closed	–	–	615
2024 Q3	$0	Buy	+1	New	+$260	﹤0.01%	547
2023 Q1	–	Sell	-1	Closed	–	–	788
2022 Q4	$0	Buy	+1	New	+$213	﹤0.01%	1138
2015 Q1	–	Sell	-100	Closed	-$10K	–	382
2014 Q4	$10K	Buy	+100	New	+$9.26K	﹤0.01%	448
2013 Q3	–	Sell	-100	Closed	-$3K	–	416
2013 Q2	$3K	Buy	+100	New	+$2.66K	﹤0.01%	440

Other funds holding ALNY

Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Summit Securities Group's ALNY Position: Q3 2026 in Review

Summit Securities Group opened a new position in Alnylam Pharmaceuticals (ALNY) in Q3 2026: 167 shares worth $41.2K. The stake represents ﹤0.01% of the portfolio and ranks #594 among its holdings. This is a return to the name: Summit Securities Group previously reported a position in ALNY as recently as Q4 2025.

Summit Securities Group first reported a position in ALNY in Q2 2013 and has held it in 6 quarters since. The position peaked at $80.3K in Q4 2025. 349 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

Summit Securities Group held 167 shares of Alnylam Pharmaceuticals worth $41.2K as of Q3 2026.
Alnylam Pharmaceuticals was a new Summit Securities Group position in Q3 2026.
Alnylam Pharmaceuticals made up ﹤0.01% of Summit Securities Group's portfolio in Q3 2026, its #594 holding.
Summit Securities Group first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 6 quarters since.
Summit Securities Group's Alnylam Pharmaceuticals position peaked at $80.3K in Q4 2025.
349 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Summit Securities Group's 13F filing for Q3 2026, filed 5 Nov 2026.